伊特卡赛肽:治疗慢性肾病继发性甲状旁腺机能亢进新药  

Etelcalcetide:A new drug for secondary hyperparathyroidism of chronic kidney disease

作　　者：郑飞[1] 张彦丽[1] 张谦[1] 巩颖[1] 顾媛媛[1] 华国栋[1] ZHENG Fei ZHANG Yan-li ZHANG Qian GONG Ying GU Yuan-yuan HUA Guo-dong(Department of Pharmacy, Dongfang Hospital of Beijing University of TCM, Beijing 100078, China)

机构地区：[1]北京中医药大学东方医院药学部,北京100078

出　　处：《药物评价研究》2017年第3期428-432,共5页Drug Evaluation Research

摘　　要：伊特卡赛肽(商品名为Parsabiv^(TM))是安进公司开发的新型二代拟钙剂,主要用于治疗慢性肾病继发性甲状旁腺机能亢进。伊特卡赛肽通过直接与钙感应受体结合来降低血钙浓度,还可以降低甲状旁腺素的水平。欧盟于2016年11月批准注射用伊特卡赛肽用于慢性肾病继发性甲状旁腺机能亢进的透析患者。介绍该药的药理作用、药动学、临床试验及不良反应研究概况。Etelcalcetide （ParsabivTM） is a second generation calcimimetic agent newly developed by Amgen, mainly used for the treatment of secondary hyperparathyroidism. Etelcalcetide not only decreases calcium concentration by directly binding with the calcium sensing receptor, but also reduces the parathyroid hormone level. The European Union has approved for chronic kidney disease patients with secondary hyperparathyroidism in dialysis with Etelcalcetide injection. This paper summarized the pharmacological effects, pharmacokinetics, clinical trials, and adverse reaction of Etelcalcetide.

关 键 词：伊特卡赛肽 新型二代拟钙剂 慢性肾病 继发性甲状旁腺机能亢进 甲状旁腺素 

分 类 号：R944.5[医药卫生—药剂学] R969.4[医药卫生—药学]